For the year ending 2025-12-31, BBLG had $2,009,191 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Research and development | 1,060,191 |
| Salaries | 650,000 |
| Insurance | 285,339 |
| Stock-based compensation | 256,358 |
| Operating expenses | 983,054 |
| Other income | 125,951 |
| Net loss | -3,108,991 |
| Stock-based compensation | 256,358 |
| Change in fair value of warrant liability | -3,967 |
| Advances on research and development contract services | 49,087 |
| Prepaid insurance | -35,233 |
| Interest receivable | 9,895 |
| Accounts payable and accrued expenses | 91,025 |
| Net cash used in operating activities | -2,691,150 |
| Proceeds from issuance of common shares from atm, net of costs | 347,549 |
| Proceeds from sale of common stock, warrants, and pre-funded warrants in public offering, net of offering costs | 4,352,792 |
| Net cash provided by financing activities | 4,700,341 |
| Net increase in cash | 2,009,191 |
| Cash, beginning of year | 3,325,131 |
| Cash, end of year | 5,334,322 |
Bone Biologics Corp (BBLG)
Bone Biologics Corp (BBLG)